Pet Scans

Studying tumor development and treatment in dogs and cats, in parallel with research on rodents and humans, could improve the successful translation of new cancer drugs.

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

© JAVIER BROSCH/SHUTTERSTOCK.COMThe vast majority of novel anticancer compounds that show promise in laboratory studies and in animal models do not make it through the rigorous and challenging translational path necessary for approval by the US Food and Drug Administration. Multiple factors contribute to the extremely low rate of successful drug development, including unexpected toxicity and/or lack of efficacy in humans, after a candidate compound has shown promise in rodent studies. As a result, researchers have begun to develop more-accurate and more-predictive model systems, such as genetically engineered murine models or patient-derived xenograft models. (See “My Mighty Mouse,” The Scientist, April 2015.) But there may be another solution to this translational problem: comparative oncology.

Studying conserved tumor subtypes across multiple species provides a unique opportunity for the scientific community to improve the drug-development pathway, specifically through the inclusion of pet dogs and cats with naturally occurring cancers. Evaluation of novel agents in such pet animals can provide valuable information regarding drug metabolism, toxicity, pharmacokinetics, pharmacodynamics, efficacy, and biomarker discovery in the context of mammalian species more similar in physiology and body size to humans. In addition, companion animals develop cancers spontaneously under normal immune surveillance mechanisms, which more faithfully recapitulate the multistep progression that occurs in people. Therefore, studying canine and feline models of cancer can generate valuable safety and efficacy data to support the further development of novel therapies.

Over the past decade, the promise of such an ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Amy K. LeBlanc

    This person does not yet have a bio.
  • Nicola Mason

    This person does not yet have a bio.
  • Timothy M. Fan

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide